Market Overview

UPDATE: JP Morgan Initiates Coverage on Lululemon on Low- to Mid- Teens Footage Growth


In a report published Wednesday, J.P. Morgan analyst Brian Tunick initiated an Overweight rating of Lululemon Athletica (NASDAQ: LULU) and initiated the price target to $84.00.

In the report, J.P. Morgan wrote, "We are initiating coverage of LULU with an OW rating and December 2014 price target of $84. After a 2013 wrought with execution issues, we see multiple levers to reaccelerate top- and bottom-line growth in FY14 and beyond, driven by low- to midteens footage growth, HSD-LDD comp gains, double-digit online growth, and margin recovery over time. 2014 potential catalysts for lulu include: 1) lapping the easier comp and margin comparisons from the 2013 Luon recall; 2) appointment of a new CEO, who could be showcased at the brand's April Analyst Day; and 3) lulu's first European store opening in London in 2Q14. LULU's multiple—while not cheap— could be poised for expansion once a new CEO is appointed and investors refocus on the brand's top-line and margin recapture prospects in 2014 and beyond."

Lululemon closed on Tuesday at $66.95.

Latest Ratings for LULU

Nov 2019MaintainsNeutral
Nov 2019Initiates Coverage OnStrong Buy
Nov 2019MaintainsOutperform

View More Analyst Ratings for LULU
View the Latest Analyst Ratings

Posted-In: Brian Tunick JP MorganAnalyst Color Initiation Analyst Ratings


Related Articles (LULU)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

VIVUS Awarded Two US Patents for Qsymia; Patent Coverage for Qsymia Extended to 2029

#PreMarket Primer: Wednesday, November 13: Will Or Won't The Fed Taper?